Subsidiary of Shanghai Pharmaceuticals Holding (601607.SH) becomes the holder of the market authorization for Ammonium Sulphate Beicterb Tablets.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Shanghai Shang Yao Zhong Xi Pharmaceutical Co., Ltd. (referred to as "Shang Yao Zhong Xi") has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The notice stated that the approval has been granted for a change in the market authorization holder for the Amisulpride Mouth-disintegrating Tablets to Shanghai Shang Yao Zhong Xi Pharmaceutical Co., Ltd. The announcement indicated that the Amisulpride Mouth-disintegrating Tablets is an improved dosage form of the Amisulpride tablets that were launched by Sanofi in France in 1986, used for the treatment of adult schizophrenia. In September 2025, Shang Yao Zhong Xi submitted an application for a change in the market authorization holder for this drug to the National Medical Products Administration, and it has been accepted for review.